Audio Journal of Oncology in Advance – March 1st, 2008
0
/
RSS Feed
Volume 16 Number 5 (March 1st, 2008) reporting from:
4th European Congress on Hematologic Malignancies (February 22-24, 2008, Paris)
Gastrointestinal Cancers Symposium (January 25-27, 2008, Orlando)
American Society of Hematology Annual Meeting (December 8-11, 2007 Atlanta)
Richard Stone
George Canellos
Dasatinib: Durable Responses in Chronic Myeloid Leukemia
Richard Stone, Dana-Farber Cancer Institute, Boston
COMMENT: George Canellos, Dana-Farber Cancer Institute, Boston
Data released at the ASH conference show that dasatinib has given durable responses in patients with chronic phase chronic myeloid leukemia for whom imatinib has failed, or who cannot tolerate imatinib. In Atlanta Richard Stone discussed his findings with Derek Thorne, who then asked George Canellos to reflect on them.
COMMENT: George Canellos, Dana-Farber Cancer Institute, Boston
Data released at the ASH conference show that dasatinib has given durable responses in patients with chronic phase chronic myeloid leukemia for whom imatinib has failed, or who cannot tolerate imatinib. In Atlanta Richard Stone discussed his findings with Derek Thorne, who then asked George Canellos to reflect on them.
Anton Hagenbeek
George Canellos
Ibritumomab Benefits Patients With Follicular Lymphoma
Anton Hagenbeek, University of Utrecht
COMMENT: George Canellos, Dana-Farber Cancer Institute, Boston
In patients with advanced-stage follicular non-Hodgkin’s lymphoma the radiolabeled antibody ibritumomab tiuxetan prolonged progression-free survival, according to a study reported at the ASH meeting. Sarah Maxwell spoke to the author Anton Hagenbeek. George Canellos put the data into context.
COMMENT: George Canellos, Dana-Farber Cancer Institute, Boston
In patients with advanced-stage follicular non-Hodgkin’s lymphoma the radiolabeled antibody ibritumomab tiuxetan prolonged progression-free survival, according to a study reported at the ASH meeting. Sarah Maxwell spoke to the author Anton Hagenbeek. George Canellos put the data into context.
Charles Hsu
Robert Mayer
Adjuvant Chemoradiotherapy: Sizable Gains In the Treatment of Pancreas Cancer
Charles Hsu, Johns Hopkins University, Baltimore
COMMENT: Robert Mayer, Dana-Farber Cancer Institute
Patients with resectable pancreas cancer lived longer when treated with adjuvant radiation plus chemotherapy, according to a study reported at the gastrointestinal cancers conference in Orlando. Charles Hsu talked with Peter Goodwin about their findings; Robert Mayer assessed the work.
COMMENT: Robert Mayer, Dana-Farber Cancer Institute
Patients with resectable pancreas cancer lived longer when treated with adjuvant radiation plus chemotherapy, according to a study reported at the gastrointestinal cancers conference in Orlando. Charles Hsu talked with Peter Goodwin about their findings; Robert Mayer assessed the work.
Pierre Fenaux
Azacitidine New Standard In High Risk Myelodysplastic Syndromes
Pierre Fenaux, Hôpital Avicenne, Paris
Phase III study results presented at ASH found the hypomethylating agent azacitidine was best for patients with high-risk MDS. Pierre Fenaux gave the details to Derek Thorne, who also heard from George Canellos.
Phase III study results presented at ASH found the hypomethylating agent azacitidine was best for patients with high-risk MDS. Pierre Fenaux gave the details to Derek Thorne, who also heard from George Canellos.
Bart Barlogie
Total Therapy Possible Cure For Multiple Myeloma?
Bart Barlogie, University of Arkansas, Little Rock
The total therapy clinical studies of multiple myeloma reported promising findings to the Hematologic Malignancies Congress in Paris. Bart Barlogie talked with Peter Goodwin about the new data from melphalan-induced tandem autologous transplants with additional thalidomide or bortezomib therapy.
The total therapy clinical studies of multiple myeloma reported promising findings to the Hematologic Malignancies Congress in Paris. Bart Barlogie talked with Peter Goodwin about the new data from melphalan-induced tandem autologous transplants with additional thalidomide or bortezomib therapy.
LISTEN
[audio:https://www.audiomedica.com/podcasting/oncology/080301ajoiaPODCAST.mp3]
To subscribe to the ASCO Audio Journal of Oncology podcast please go to ASCO Audio Journal of Oncology in Advance Presentations or click here.
Share
